Lmr Partners LLP Cardiff Oncology, Inc. Transaction History

Lmr Partners LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.46 - $5.91 $19,127 - $77,426	13,101 New	13,101 $69,000
Q2 2022 Aug 15, 2022	BUY	$1.17 - $2.61 $15,893 - $35,454	13,584 New	13,584 $30,000
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $155,157 - $234,253	-23,332 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $212,321 - $456,607	23,332 New	23,332 $216,000

125

25.3M

866K

203K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $206M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.